Previous 10 | Next 10 |
Mereo BioPharma is a biopharma company focused on oncology and rare diseases, suiting a market cap of $388M USD at the time of this article. The company currently has great partnerships in place, which will increase the chances of success as well as my confidence as an investor. M...
MREO came to some prominence after Ultragenyx gave it a nice deal in December 2020. Its lead asset etigilimab has some early interesting data. It will take a few more years for the company to garner more investor interest. For further details see: Mereo BioPharma: Underf...
LONDON and REDWOOD CITY, Calif., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on oncology and rare diseases, today announced that Dr. Denise Scots-Knight,...
5 Biotech Penny Stocks Trending This Week In the past twelve months, biotech penny stocks have become all the rage. Regardless of whether they are working on a covid treatment, investors have shown a massive propensity for penny stocks in the biotechnology industry. The term biotech...
Gainers: [[EH]] +18.6%. [[VSTM]] +17.7%. [[CSOD]] +11.4%. [[SSP]] +10.93%. [[MREO]] +10.6%.Losers: [[MVIS]] -10.4%. [[EPSN]] -7.5%. [[BLCT]] -4.7%. [[DRVN]] -3.7%. [[FELE]] -3.4%. For further details see: EH, CSOD, MVIS and DRVN among after-hours movers
LONDON and REDWOOD CITY, Calif., Feb. 12, 2021 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on oncology and rare diseases, announced the closing of its previously annou...
Mereo BioPharma (MREO) traded 1.64% higher premarket after pricing its underwritten public offering of 34.5M ADSs at $2.90/ADS; underwriters granted 30-day option to purchase up to 5.18M additional ADSs.Each ADS represents five ordinary shares of Mereo.Gross proceeds are expected to...
LONDON and REDWOOD CITY, Calif., Feb. 10, 2021 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on oncology and rare diseases, today announced the pricing of an underwritte...
LONDON and REDWOOD CITY, Calif., Feb. 09, 2021 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on oncology and rare diseases, today announced that it intends to offer and ...
Gainers: [[ACY]] +39.4%. [[MREO]] +5.0%. [[SOAC]] +4.2%. [[GTHX]] +4.0%. [[STPK]] +3.4%.Losers: [[AIRT]] -23.1%. [[SCPS]] -9.4%. [[TRITW]] -6.8%. [[ID]] -6.0%. [[VET]] -4.9%. For further details see: ACY, MREO, AIRT and ID among after-hours movers
News, Short Squeeze, Breakout and More Instantly...
Mereo BioPharma Group Company Name:
MREO Stock Symbol:
NASDAQ Market:
Mereo BioPharma Group Website:
2024-06-20 09:00:06 ET Joseph Schwartz from Leerink Partners issued a price target of $8.00 for MREO on 2024-06-20 07:21:00. The adjusted price target was set to $8.00. At the time of the announcement, MREO was trading at $3.98. The overall price target consensus is at $...
2024-06-14 10:45:03 ET Cleanspark Inc (CLSK) CLSK is trading UP for the last 5 days, and it at trading at $18.30 with volume of 12,068,034 and a one day change of $0.33 (1.84%). Cleanspark Inc has a 52-week low of 3.38 and a 52-week high of $24.72. The business's 50-day moving avera...
LONDON, June 14, 2024 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced the pricing of an underwritten offering of 12,531,300 of its American Dep...